DWTX highlights Halneuron potential for chemotherapy-induced neuropathic pain
Halneuron, a selective NaV1.7 inhibitor, is positioned as a first-in-class, durable therapy for chemotherapy-induced neuropathic pain, citing durable efficacy and a strong safety profile in clinical trials.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.